Target Information

Target General Infomation
Target ID
T47415
Former ID
TTDI02337
Target Name
HLA class I antigen B-7
Gene Name
HLA-B
Synonyms
HLA class I histocompatibility antigen, B7 alpha chain; HLAB; MHC class I antigen B*7; HLA-B
Target Type
Clinical Trial
Disease Melanoma [ICD9: 172; ICD10: C43]
Function
Involved in the presentation of foreign antigens to the immune system.
BioChemical Class
MHC class I family
UniProt ID
P01889
Sequence
MLVMAPRTVLLLLSAALALTETWAGSHSMRYFYTSVSRPGRGEPRFISVGYVDDTQFVRF
DSDAASPREEPRAPWIEQEGPEYWDRNTQIYKAQAQTDRESLRNLRGYYNQSEAGSHTLQ
SMYGCDVGPDGRLLRGHDQYAYDGKDYIALNEDLRSWTAADTAAQITQRKWEAAREAEQR
RAYLEGECVEWLRRYLENGKDKLERADPPKTHVTHHPISDHEATLRCWALGFYPAEITLT
WQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEP
SSQSTVPIVGIVAGLAVLAVVVIGAVVAAVMCRRKSSGGKGGSYSQAACSDSAQGSDVSL
TA
Drugs and Mode of Action
Drug(s) Velimogene aliplasmid Drug Info Phase 3 Melanoma [521540]
Modulator Velimogene aliplasmid Drug Info [530830]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
References
Ref 521540ClinicalTrials.gov (NCT00050388) Phase II Trial of Allovectin-7 for Head and Neck Cancer. U.S. National Institutes of Health.
Ref 530830Velimogene aliplasmid. Expert Opin Biol Ther. 2010 May;10(5):841-51.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.